The latest market report published by Credence Research, Inc. “Global Angina Pectoris Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022,” the angina pectoris treatment market was valued at USD 7,962.8 Mn in 2015, and is expected to reach USD 12,589.6 Mn by 2022, expanding at a CAGR of 5.2% from 2016 to 2022.
Browse the full report Angina Pectoris Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/angina-pectoris-treatment-market
According to American College of Cardiology, Chronic angina affects over seven million North Americans and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). The market experts suggest that, various approaches have included new pharmacologic antianginal agents, interventional approaches, and therapeutic angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the first line drugs and the largest drug class segment in angina pectoris treatment market. The major factors assisting growth of beta adrenergic blockers are the efficiency, fast onset of action, accessibility to patients and high patient compliance. A few drugs in phase III of clinical trials are observed as the most potential molecules in the angina pectoris treatment. These potential molecules are such as Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.
The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as the most potential drug molecule in angina pectoris treatment in the near future. According to Tasly Pharmaceuticals, Inc. the study completion of phase III trial for Dantonic would be by December 2016. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. Thus, according to its exceptional results projected in phase II suggest that Dantonic would be the most potential pipeline drug for angina pectoris treatement.
For More Information, List of Figure, Tables And TOC Visit – http://www.credenceresearch.com/report/angina-pectoris-treatment-market
Key Market Movements:
- Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
- High demand for target specific and tailored drugs for angina pectoris treatment
- In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Web: Credence Research
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Address:105 N 1st ST #429
City: SAN JOSE
Country: United States